Janux tries to improve on the masking approach
Meanwhile, investors await key clinical data.
Nanjing Leads tests investor appetite for Lag3
But BeOne canned its alcestobart deal in May.
5,000 patients later Roche scraps its TIGIT
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
Novel cadherin conjugates enter the clinic
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
FDA rejects Replimune’s oncolytic virus
There are questions about vuso-vec’s supporting and confirmatory trials.
